9.4.24 - Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Presentations and Poster at ERS Congress READ MORE
5.21.24 - Kinaset Therapeutics Debuts Positive Outcomes Data from Phase 1b Study of KN-002 at the 2024 American Thoracic Society (ATS) International Conference READ MORE
12.21.23 - Kinaset Therapeutics to Participate in the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference READ MORE
12.7.23 - Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting READ MORE
5.15.23 - Kinaset Therapeutics to Present at the American Thoracic Society (ATS) 2023 Respiratory Innovation Summit READ MORE
7.7.22 - Kinaset Therapeutics Appoints Christopher O’Brien, MD, PhD, FCCP, as Chief Medical Officer READ MORE
9.15.21 - Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients READ MORE
11.30.20 - Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory READ MORE
